Roche Receives FDA Approval for Columvi in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche today announced that the FDA has granted accelerated approval to Columvi (glofitamab-gxbm) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma after two or more prior lines of systemic therapy.